This is an archived file of a live webcast that took place on August 2, 2016.
In this webinar, clinicians, researchers and a patient share the current state of science and safety around the cancer drug nilotinib for the treatment of Parkinson's disease. Our panel also discuss plans for future testing.
Title: Update on Cancer Drug Nilotinib for Parkinson's Disease
Duration: 1 hour
MJFF is not offering CME credit for this webinar. Visit www.michaeljfox.org/webinars for our library of CME-accredited Third Thursdays webinars.